Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells

In human proximal tubules, organic cations are taken up from blood into cells by human organic cation transporter 2 [hOCT2/solute carrier (SLC) 22A2] and then eliminated into the lumen by apical H+/organic cation antiporters, human multidrug and toxin extrusion 1 (hMATE1/SLC47A1) and hMATE2-K (SLC47A2). To evaluate drug interactions of cationic drugs in the secretion process, epithelial cells engineered to express both hOCT2 and hMATE transporters are required to simultaneously evaluate drug interactions with renal basolateral and apical organic cation transporters. In the present study, therefore, we assessed the drug interaction between cimetidine and metformin with double-transfected Madin-Darby canine kidney cells stably expressing both hOCT2 and hMATE1 as an in vitro model of the proximal tubular epithelial cells. The basolateral-to-apical transport and intracellular accumulation of [14C]metformin by a double transfectant were markedly inhibited by 1 mM cimetidine at the basolateral side. On the other hand, 1 μM cimetidine at the basolateral side moderately decreased the basolateral-to-apical transport of [14C]metformin and significantly increased the intracellular accumulation of [14C]metformin from the basolateral side, suggesting that cimetidine at a low concentration inhibits apical hMATE1, rather than basolateral hOCT2. Actually, in concentration-dependent inhibition studies by a single transporter expression system, such as human embryonic kidney 293 stably expressing hMATE1, hMATE2-K, or hOCT2, cimetidine showed higher affinity for hMATEs than for hOCT2. These results suggest that apical hMATE1 is involved in drug interactions between cimetidine and cationic compounds in the proximal tubular epithelial cells.

[1]  B. Feng,et al.  Effect of Human Renal Cationic Transporter Inhibition on the Pharmacokinetics of Varenicline, a New Therapy for Smoking Cessation: An In Vitro–In Vivo Study , 2008, Clinical pharmacology and therapeutics.

[2]  Tomoko Sato,et al.  Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. , 2008, Biochemical pharmacology.

[3]  Hiroshi Omote,et al.  A human transporter protein that mediates the final excretion step for toxic organic cations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Shin,et al.  Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin , 2008, Clinical pharmacology and therapeutics.

[5]  K. Inui,et al.  Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1. , 2007, American journal of physiology. Renal physiology.

[6]  A. Somogyi,et al.  Reduction of metformin renal tubular secretion by cimetidine in man. , 1987, British journal of clinical pharmacology.

[7]  H. Kasanuki,et al.  Effect of cimetidine and probenecid on pilsicainide renal clearance in humans , 2000, Clinical pharmacology and therapeutics.

[8]  S. Masuda,et al.  Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. , 2007, Biochemical pharmacology.

[9]  H. Takane,et al.  Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin , 2006, Journal of Human Genetics.

[10]  H. Saito,et al.  Mechanisms of gentamicin transport in kidney epithelial cell line (LLC-PK1). , 1986, The Journal of pharmacology and experimental therapeutics.

[11]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[12]  Brian Tomlinson,et al.  OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine , 2008, Pharmacogenetics and genomics.

[13]  S. Masuda,et al.  Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1–3 and Multidrug and Toxin Extrusion Family) , 2006, Journal of Pharmacology and Experimental Therapeutics.

[14]  A. Somogyi,et al.  Cimetidine-procainamide pharmacokinetic interaction in man: Evidence of competition for tubular secretion of basic drugs , 2004, European Journal of Clinical Pharmacology.

[15]  Meng Li,et al.  Drugdrug interactions involving membrane transporters in the human kidney , 2006, Expert opinion on drug metabolism & toxicology.

[16]  K. Speeg,et al.  Cimetidine inhibits renal procainamide clearance , 1984, Clinical pharmacology and therapeutics.

[17]  A. Somogyi,et al.  Effect of cimetidine on renal and hepatic drug elimination: Studies with triamterene , 1986, Clinical pharmacology and therapeutics.

[18]  S. Masuda,et al.  Distinct Characteristics of Organic Cation Transporters, OCT1 and OCT2, in the Basolateral Membrane of Renal Tubules , 2001, Pharmaceutical Research.

[19]  S. Higuchi,et al.  Polymorphism in human organic cation transporters and metformin action. , 2008, Pharmacogenomics.

[20]  Osamu Ogawa,et al.  Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. , 2007, Biochemical pharmacology.

[21]  Yuichi Sugiyama,et al.  Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. , 2005, Annual review of pharmacology and toxicology.

[22]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[23]  R. Maynard,et al.  The Pharmacological Basis of Therapeutics. 9th ed , 1997 .

[24]  M. Okuda,et al.  Creatinine Transport by Basolateral Organic Cation Transporter hOCT2 in the Human Kidney , 2004, Pharmaceutical Research.

[25]  H. Koepsell,et al.  Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications , 2007, Pharmaceutical Research.

[26]  O. Ogawa,et al.  Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. , 2006, Journal of the American Society of Nephrology : JASN.

[27]  I. Tamai,et al.  TRANSPORT OF THE DOPAMINE D2 AGONIST PRAMIPEXOLE BY RAT ORGANIC CATION TRANSPORTERS OCT1 AND OCT2 IN KIDNEY , 2005, Drug Metabolism and Disposition.

[28]  K. Inui,et al.  Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). , 2008, Biochemical pharmacology.

[29]  K. Giacomini,et al.  Mechanisms of interactions between organic anions and the organic cation transporter in renal brush border membrane vesicles. , 1990, Biochemical pharmacology.

[30]  A. Somogyi,et al.  Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. , 1986, The Journal of pharmacology and experimental therapeutics.

[31]  Christopher J Endres,et al.  The role of transporters in drug interactions. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.